Drug
Mericitabine clinical trials
Also written RO5024048.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Danoprevir (2) · Peginterferon alfa-2a (2) · Ribavirin (1) · Ritonavir (1)
Studies
Open first, then newest update. How each study uses mericitabine is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01482390Written as Mericitabine
- ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based TreatmentCompletedPhase 2Hoffmann-La RocheNCT01628094Written as RO5024048
- A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048CompletedPhase 1Hoffmann-La RocheNCT01099904Written as RO5024048
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4CompletedPhase 2Hoffmann-La RocheNCT01057667Written as RO5024048
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedPhase 2Hoffmann-La RocheNCT01278134Written as RO5024048
- A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01331850Written as RO5024048
- A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C PatientsCompletedPhase 1Hoffmann-La RocheNCT00801255Written as RO5024048
- A Study of RO5024048 in Japanese and Caucasian Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01152671Written as RO5024048
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedPhase 2Hoffmann-La RocheNCT00869661Written as RO5024048
- A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01482403Written as mericitabine
- A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated CirrhosisCompletedPhase 2Hoffmann-La RocheNCT01483742Written as RO5024048
- Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and RibavirinCompletedPhase 1/2PharmassetNCT00382798Written as RO5024048
Given in every arm · 2 — mericitabine is usual care beside what is tested
- A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.CompletedPhase 2Hoffmann-La RocheNCT00377182Written as RO5024048 1500mg
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor TreatmentWithdrawnPhase 2Hoffmann-La RocheNCT01579019Written as RO5024048
Codes
What other systems call mericitabine · ClinicalTrials.gg INT005699
- UNII (FDA) TA63JX8X52MERICITABINEConfirmed FDA, Wikidata
- Wikidata Q21099044mericitabineConfirmed FDA, Wikidata
- NCI Thesaurus C98959MericitabineOne source FDA
- DrugBank DB12045One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TA63JX8X52 | MERICITABINE | Confirmed FDA, Wikidata |
| Wikidata | Q21099044 | mericitabine | Confirmed FDA, Wikidata |
| NCI Thesaurus | C98959 | Mericitabine | One source FDA |
| DrugBank | DB12045 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.